Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta.
Arndt, J.W., Qian, F., Smith, B.A., Quan, C., Kilambi, K.P., Bush, M.W., Walz, T., Pepinsky, R.B., Bussiere, T., Hamann, S., Cameron, T.O., Weinreb, P.H.(2018) Sci Rep 8: 6412-6412
- PubMed: 29686315 
- DOI: 10.1038/s41598-018-24501-0
- Primary Citation of Related Structures:  
6CNR, 6CO3 - PubMed Abstract: 
Aducanumab, a human-derived antibody targeting amyloid-β (Aβ), is in Phase 3 clinical trials for the treatment of Alzheimer's disease. Biochemical and structural analyses show that aducanumab binds a linear epitope formed by amino acids 3-7 of the Aβ peptide ...